TABLE 1.

Treatments of the differentiated MDMs.

Sample Description	0 to 24 h	24 to 48 h
Untreated cells	cRPMI (3 mL)	cRPMI not changed
Negative control	cRPMI (2.5 mL)	Vehicle (0.5 mL)
LPS	cRPMI (2.5 mL) with LPS (1 μg/mL)	Vehicle (0.5 mL)
LPS + MP10	cRPMI (2.5 mL) with LPS (1 μg/mL)	MP (0.5 mL of 0.06 mM stock in cRPMI). Final concentration 0.01 mM
MP control	cRPMI (2.5 mL)	MP (0.5 mL of 0.06 mM stock in cRPMI). Final concentration 0.01 mM
IL-4+IL-13 (M2 control)	cRPMI with IL-4 and IL-13 (20 ng/mL)	Treatment not changed
Triton X-100 (positive control for LDH)	cRPMI (3 mL)	Triton X-100 (0.3 mL). Final concentration 0.2% (v/v)

Vehicle is a solution of absolute ethanol (0.005% in cRPMI; v/v).